CUAMC
PVLA

China Universal Asset Management Company’s Palvella Therapeutics PVLA Stock Holding History

China Universal Asset Management Company’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$207K Buy
1,357
+357
+36% +$43.3K 0.01% 349
2026
Q1 		$125K Sell
1,000
-600
-38% -$62.6K 0.01% 391
2025
Q4 		$167K Buy
+1,600
New +$136K 0.01% 365

Other funds holding PVLA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
CAM
Clio Asset Management Charlottesville, Virginia $126M AUM 16.01% 1-Year Est. Return
LCG
Lisanti Capital Growth New York $455M AUM 218.66% 1-Year Est. Return

China Universal Asset Management Company's PVLA Position: Q2 2026 in Review

China Universal Asset Management Company increased its Palvella Therapeutics (PVLA) stake by 36% in Q2 2026, buying an estimated $43.3K and bringing the position to 1,357 shares worth $207K. The position accounts for 0.01% of the portfolio, ranked #349.

China Universal Asset Management Company first reported a position in PVLA in Q4 2025 and has held it in 3 quarters since. 96 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • China Universal Asset Management Company held 1,357 shares of Palvella Therapeutics worth $207K as of Q2 2026.
  • China Universal Asset Management Company bought 357 Palvella Therapeutics shares in Q2 2026, an estimated $43.3K.
  • Palvella Therapeutics made up 0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #349 holding.
  • China Universal Asset Management Company first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 96 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.